Mutations in the BRCA1 gene that are either inherited (germline) or acquired (somatic) might not be key to the initiation of prostate cancer, as previously thought, suggests the first study of its kind, published online in the open access journal BMJ Oncology.
If confirmed in further studies, the findings suggest that it may be time to reassess current treatment with PARP (poly(ADP-ribose) polymerase) inhibitor drugs, which block the ability of cells, including cancer cells, to repair DNA damage, in men with BRCA1 genetic variants, say the researchers.
A linked editorial suggests that the findings pave the way for greater refinement of genetic testing and personalised treatment for men with prostate cancer.
Prostate cancer is the most common cancer in men, and genetic variants in DNA damage repair…